Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

MW073

Add links
From Wikipedia, the free encyclopedia

MW073
Clinical data
Other namesMW-073
Drug classSerotonin 5-HT2B receptor antagonist
ATC code
  • None
Identifiers
  • 4-methyl-N-[2-(4-methylpiperazin-1-yl)ethyl]-6-naphthalen-2-ylpyridazin-3-amine
PubChem CID
ChemSpider
Chemical and physical data
FormulaC22H27N5
Molar mass361.493 g·mol−1
3D model (JSmol)
  • CC1=CC(=NN=C1NCCN2CCN(CC2)C)C3=CC4=CC=CC=C4C=C3
  • InChI=1S/C22H27N5/c1-17-15-21(20-8-7-18-5-3-4-6-19(18)16-20)24-25-22(17)23-9-10-27-13-11-26(2)12-14-27/h3-8,15-16H,9-14H2,1-2H3,(H,23,25)
  • Key:IBOOAZHRKKSRLF-UHFFFAOYSA-N

MW073 is a serotonin 5-HT2B receptor antagonist which is used in scientific research.[1][2][3][4][5] It is a highly selective antagonist of the serotonin 5-HT2B receptor.[3][2] The drug is orally active in animals and is said to have a favorable drug-like profile.[3][2] It produces antiaggressive effects without causing sedation or altering locomotor activity or anxiety in an animal model of Alzheimer's disease.[3][2] Similarly, it produces neuroprotective, neurorestorative, and pro-cognitive-like effects in such models.[3][2][5] MW073 was first described in the scientific literature by 2024.[4][2][3][5] There is interest in MW073 for the potential treatment of Alzheimer's disease and other conditions.[3][2]

See also

[edit]

References

[edit]
  1. ↑ "Delving into the Latest Updates on MW073 with Synapse". Synapse. 9 May 2026. Retrieved 9 June 2026.
  2. 1 2 3 4 5 6 7 Roy SM, Acquarone E, Argyrousi EK, Zhang H, Staniszewski A, Inoue A, et al. (2025). "Optimized 5-HT2b inhibitors for neuropsychiatric syndromes with cognitive dysfunction". Alzheimer's & Dementia. 11 (1) e70073. New York, N. Y. doi:10.1002/trc2.70073. PMC 11947739. PMID 40151398.
  3. 1 2 3 4 5 6 7 Acquarone E, Roy SM, Staniszewski A, Watterson DM, Arancio O (February 2026). "The Highly Selective 5-HT2B Receptor Antagonist MW073 Mitigates Aggressive Behavior in an Alzheimer's Disease Mouse Model". Cells. 15 (3). doi:10.3390/cells15030273. PMC 12896383. PMID 41677635.
  4. 1 2 Acquarone E, Argyrousi EK, Arancio O, Watterson DM, Roy SM (2024). "The 5HT2b Receptor in Alzheimer's Disease: Increased Levels in Patient Brains and Antagonist Attenuation of Amyloid and Tau Induced Dysfunction". Journal of Alzheimer's Disease. 98 (4): 1349–1360. doi:10.3233/JAD-240063. PMC 11091653. PMID 38578894.
  5. 1 2 3 Roy S, Acquarone E, Ziarek JJ, Ottavio A, Watterson DM (2026). "MW073 Treatment Attenuates Synaptic Dysfunction, Cognition-Related Behavior Deficits, and Aggression in Alzheimer's Disease Models (Abstract ID: 273213)". The Journal of Pharmacology and Experimental Therapeutics. 393 (5) 104835. doi:10.1016/j.jpet.2026.104835.
Retrieved from "https://en.wikipedia.org/w/index.php?title=MW073&oldid=1358502771"